Epidemic Characteristics of Carbapenem-Resistant Klebsiella pneumoniae in the Pediatric Intensive Care Unit of Yanbian University Hospital, China

Figures & data

Table 1 Sequences of the Primers (Carbapenemase Genes and Other β-Lactamase Genes)

Target Gene	Primer	Primer Sequence (5′–3′)	Product Size (bp)	Annealing Temperature (°C)
KPC	KPC-F	TGTCACTGTATCGCCGTC	1010	58
	KPC-R	CTCAGTGCTCTACAGAAAACC
IMP1	IMP1-full-F	TGAGCAAGTTATCTGTATTC	740	55
	IMP1-full-R	TTAGTTGCTTGGTTTTGATG
IMP2	IMP2-full-F	GGCAGTCGCCCTAAAACAAA	737	55
	IMP2-full-R	TAGTTACTTGGCTGTGATGG
NDM	NDM-full F	ATGGAATTGCCCAATATTATGCAC	816	61
	NDM-full R	TCAGCGCAGCTTGTCGGC
VIM1	VIM1-full-F	TTATGGAGCAGCAACCGATGT	920	55
	VIM1-full-R	CAAAAGTCCCGCTCCAACGA
VIM2	VIM2-full-F	AAAGTTATGCCGCACTCACC	865	55
	VIM2-full-R	TGCAACTTCATGTTATGCCG
OXA-48	OXA-48-F	GCGTGGTTAAGGATGAACAC	438	52
	OXA-48-R	CATCAAGTTCAACCCAACCG
CTX-M1 group	CM3-full-F	TTTCGGAAGCATAAAATCGG	1021	56
	CM3-full-R	GGCGATAAACAAAAACGGAA
CTX-M2 group	P3-F	ATGATGACTCAGAGCATTCG	832	65
	P2b-R	TCCCGACGGCTTTCCGCCTT
CTX-M3 group	YW3459-F	AAAAATGATTGAAAGGTGGT	1242	56
	YW3460-R	GTGAAGAAGGTGTTGCTGAC
DHA	DHA1-F	CTGATGAAAAAATCGTTATC	1141	56
	DHA1-R	ATTCCAGTGCACTCAAAATA
CMY	CMY-F	TGTCAACACGGTGCAAATCA	1346	56
	CMY-R	AGCAACGACGGGCAAAATG
ACT	ACT-F	CGAACGAATCATTATTCAGCACCG	1518	56
	ACT-R	CGGCAATGTTTACTACACAGCG

Table 2 Microbiological and Molecular Characteristics, Antibiotic Susceptibilities (mg/L) of Carbapenem-Resistant K. pneumoniae

Isolate Number	Specimen	Gender	Age	Date of Isolation (y)	mCIM (mm)	Carbapenemase	CTX–M	DHA	ST	PFGE Pattern	MEM	IPM	ATM	FEP	CAZ	CTX	TZP	AMK	CIP	LVX	POL	GEN	SXT	TCY	CHL
1	Blood	M	7m	2015	6	KPC-2	CTX-M-65	–	11	A	>8	>8	>16	>16	>16	>32	>64	>32	>2	>8	≤0.5	>8	≤0.5	4	>16
2	Sputum	F	16d	2015	6	KPC-2	CTX-M-65	–	11	A	>8	>8	>16	>16	>16	>32	>64	>32	>2	>8	≤0.5	>8	≤0.5	4	>16
3	Blood	M	9d	2015	6	KPC-2	CTX-M-65	–	11	A	>8	>8	>16	>16	>16	>32	>64	>32	>2	>8	≤0.5	>8	≤0.5	4	>16
4	Blood	F	9d	2015	6	KPC-2	CTX-M-65	–	11	A	>8	>8	>16	>16	>16	>32	>64	>32	>2	>8	≤0.5	>8	≤0.5	4	>16
5	Blood	M	11d	2015	6	KPC-2	CTX-M-65	–	11	A	>8	>8	>16	>16	>16	>32	>64	>32	>2	>8	≤0.5	>8	≤0.5	4	>16
6	Blood	M	22d	2015	6	KPC-2	CTX-M-65	–	11	A	>8	>8	>16	>16	>16	>32	>64	>32	>2	>8	≤0.5	>8	≤0.5	4	>16
7	Sputum	M	1m	2015	6	KPC-2	CTX-M-65	–	11	A	>8	>8	>16	>16	>16	>32	>64	>32	>2	>8	≤0.5	>8	≤0.5	4	>16
10	Blood	F	9d	2017	6	NDM-1	–	DHA1	1224	C	>8	>8	>16	>16	>16	>32	>64	≤8	≤0.5	≤1	≤0.5	≤2	>2	>8	≤4
11	Sputum	M	1m	2017	6	NDM-1	–	DHA1	1224	C	>8	>8	>16	>16	>16	>32	>64	≤8	≤0.5	≤1	≤0.5	≤2	>2	>8	≤4
12	Blood	M	12d	2017	6	NDM-1	–	DHA1	1224	C	>8	>8	>16	>16	>16	>32	>64	≤8	≤0.5	≤1	≤0.5	≤2	>2	>8	≤4
13	Blood	M	8d	2017	6	NDM-1	–	DHA1	1224	C	8	8	>16	>16	>16	>32	>64	≤8	≤0.5	≤1	≤0.5	≤2	>2	>8	≤4
14	Blood	M	8d	2017	6	NDM-1	–	DHA1	1224	D	>8	>8	>16	>16	>16	>32	>64	≤8	≤0.5	≤1	≤0.5	≤2	>2	>8	≤4
15	Blood	F	9d	2017	6	NDM-1	–	DHA1	1224	D	>8	>8	>16	>16	>16	>32	>64	≤8	≤0.5	≤1	≤0.5	≤2	>2	>8	≤4
77	Blood	M	10d	2018	6	KPC-2	CTX-M-65	–	11	B	>8	>8	>16	>16	>16	>32	>64	>32	>2	>8	1	>8	≤0.5	4	8

Abbreviations: MEM, meropenem; IPM, imipenem; ATM, aztreonam; FEP, cefepime; CAZ, ceftazidime; CTX, cefotaxime; TZP, piperacillin/tazobactam; AMK, amikacin; CIP, ciprofloxacin; LVX, levofloxacin; POL, polymyxin; GEN, Gentamicin; SXT, trimethoprim/sulfamethoxazole; TCY, tetracycline; CHL, chloramphenicol.

Figure 1 Dendrogram of patterns for carbapenem-resistant K. pneumonia isolates obtained by PFGE.